Found 37 Lung Cancer trials
A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase 2 Open-label Study to Evaluate the Safety and Efficacy of VGT-309 a Tumor-Targeted Activatable Fluorescent Imaging Agent to Identify Cancer in Subjects Undergoing Lung Cancer Surgery
To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of VGT-309 to detect cancer utilizing near-infrared (NIR) fluorescence and histopathology results. 1. Sensitivity: defined as the probability that the tissue fluoresces when it is cancer, as confirmed by histology (TP/(TP+FN)) 2. Specificity: defined as the …
A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.
AN UN-BLINDED INTRA-PATIENT COMPARISON OF TRANSBRONCHIAL FORCEPS BIOPSY AND CRYOBIOPSY FOR PERIPHERAL PULMONARY LESIONS
Peripheral lung nodules seen on CT scans require a diagnostic evaluation as they commonly represent small, treatable lung cancers. In order to diagnose these lung lesions, bronchoscopy with small lung biopsies is often the preferred first step. However, this procedure is not always successful as not all biopsies obtain enough …
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …
A Phase 1 Study of the Highly-selective RET
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors
study of surufatinib in combination with tislelizumab will evaluate the safety, and tolerability in patients with advanced solid tumors.
UPCC 14920 A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
PILOT STUDY TO ASSESS LUNG FUNCTION USING PERFUSION BLOOD VOLUME DUAL ENERGY CT AND 4DCT DERIVED LUNG VENTILATION IMAGING
The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation when a contrast-enhanced 4DCT is planned. The primary goal is to quantify the reproducibility of lung …
A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects with Oligometastatic Tumors in the Lung
The primary objective of the study is to evaluate the safety and effectiveness of the NEUWAVETM FLEX MC Microwave Ablation System and Accessories used in transbronchial ablation procedures for adult subjects with oligometastatic tumors ( 2cm) in the lung. Technique Efficacy: Ablation of the target tumor(s) with the ablation zone …
GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)
This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).
Please choose between Voice or SMS based delivery of verification code
or